SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-006992
Filing Date
2021-05-13
Accepted
2021-05-13 07:30:49
Documents
62
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akro-20210331x10q.htm 10-Q 1330983
2 EX-31.1 akro-20210331ex311f44f41.htm EX-31.1 10732
3 EX-31.2 akro-20210331ex3125c8d59.htm EX-31.2 11640
4 EX-32.1 akro-20210331ex3213f7e66.htm EX-32.1 10471
  Complete submission text file 0001558370-21-006992.txt   5160142

Data Files

Seq Description Document Type Size
5 EX-101.INS akro-20210331.xml EX-101.INS 1051949
6 EX-101.SCH akro-20210331.xsd EX-101.SCH 40217
7 EX-101.CAL akro-20210331_cal.xml EX-101.CAL 36169
8 EX-101.DEF akro-20210331_def.xml EX-101.DEF 101142
9 EX-101.LAB akro-20210331_lab.xml EX-101.LAB 383034
10 EX-101.PRE akro-20210331_pre.xml EX-101.PRE 271156
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38944 | Film No.: 21917205
SIC: 2834 Pharmaceutical Preparations